We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $10.2B
1-Year Est. Return 149.19%
This Fund
S&P 500
This Quarter Est. Return
+57.39%
1 Year Est. Return
+149.19%
3 Year Est. Return
+425.03%
5 Year Est. Return
+775.33%
10 Year Est. Return
+45,729.2%
AUM
$570M
AUM Growth
+$120M
Cap. Flow
-$68.6M
Cap. Flow %
-12.04%
Top 10 Hldgs %
59.83%
Holding
55
New
13
Increased
13
Reduced
16
Closed
7

Top Buys

Rank Stock Value
1
ACAD icon
Acadia Pharmaceuticals
ACAD
+$15.7M
2
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$12.8M
3
AERI
Aerie Pharmaceuticals
AERI
+$11M
4
SGEN
Seagen Inc. Common Stock
SGEN
+$6.71M
5
AGIO icon
Agios Pharmaceuticals
AGIO
+$6.53M

Top Sells

Rank Stock Value
1
CPXX
CELATOR PHARMACEUTICALS INC. COMMON STOCK
CPXX
+$33.9M
2
TSRO
TESARO, Inc.
TSRO
+$22.1M
3
MDVN
MEDIVATION, INC.
MDVN
+$16.9M
4
RLYP
RELYPSA INC COM
RLYP
+$11.3M
5
GILD icon
Gilead Sciences
GILD
+$9.05M

Sector Composition

Rank Sector Weight
1 Healthcare 83.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SRPT icon
26
CALL
Sarepta Therapeutics
SRPT
$1.57B
$6.03M 1.06%
190,000
-434,600
-70% -$13.1M
ALIM
27
DELISTED
Alimera Sciences
ALIM
$5.33M 0.93%
+238,333
New +$5.49M
TRIL
28
DELISTED
Trillium Therapeutics Inc.
TRIL
$4.67M 0.82%
316,020
+87,323
+38% +$1.01M
CRVS icon
29
Corvus Pharmaceuticals
CRVS
$1.12B
$4.42M 0.77%
268,369
+193,569
+259% +$2.79M
FBIO icon
30
Fortress Biotech
FBIO
$104M
$4.03M 0.71%
90,442
+2,000
+2% +$85.1K
KA
31
DELISTED
Kineta, Inc. Common Stock
KA
$2.8M 0.49%
+1,283
New +$2.38M
INNL
32
DELISTED
Innocoll Holdings plc Ordinary Shares
INNL
$2.72M 0.48%
468,148
– –
ASMB icon
33
Assembly Biosciences
ASMB
$498M
$1.93M 0.34%
22,343
+594
+3% +$45.9K
OTLK icon
34
Outlook Therapeutics
OTLK
$183M
$1.92M 0.34%
2,818
-99
-3% -$62.9K
CLLS
35
Cellectis
CLLS
$277M
$1.41M 0.25%
58,671
+16,000
+37% +$418K
ARAV
36
DELISTED
Aravive, Inc. Common Stock
ARAV
$1.17M 0.21%
+15,957
New +$1.15M
OMED
37
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
$972K 0.17%
+85,000
New +$989K
ASND icon
38
Ascendis Pharma A/S
ASND
$16B
$909K 0.16%
+45,203
New +$746K
AGEN
39
CALL
Agenus
AGEN
$312M
$800K 0.14%
+50,950
New +$5.84M
CEMP
40
DELISTED
Cempra, Inc.
CEMP
$726K 0.13%
+30,000
New +$646K
VCEL icon
41
Vericel Corp
VCEL
$2.35B
$604K 0.11%
215,744
-39,256
-15% -$90.5K
IBRX icon
42
ImmunityBio
IBRX
$7.51B
$563K 0.1%
72,412
– –
DRNA
43
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$271K 0.05%
+46,082
New +$162K
ONSIZ
44
DELISTED
Oncobiologics, Inc. Series B Warrant
ONSIZ
$233K 0.04%
233,333
– –
ONSIW
45
DELISTED
Oncobiologics, Inc. Series A Warrant Expiring 2/18/2019
ONSIW
$112K 0.02%
233,333
– –
IMMU
46
CALL
DELISTED
Immunomedics Inc
IMMU
$53K 0.01%
300,800
-153,100
-34% -$428K
SRPT icon
47
PUT
Sarepta Therapeutics
SRPT
$1.57B
$2K ﹤0.01%
75,600
-1,256,400
-94% -$38M
CYTK icon
48
Cytokinetics
CYTK
$10.5B
– –
-503,900
Closed -$4.78M
GILD icon
49
Gilead Sciences
GILD
$162B
– –
-108,500
Closed -$9.05M
OEF icon
50
PUT
iShares S&P 100 ETF
OEF
$20.1B
– –
-50,000
Closed -$19K
1
2
3

Similar funds

IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Avoro Capital Advisors's Q3 2016 Portfolio in Review

As of Q3 2016, Avoro Capital Advisors held 55 positions worth $570M, up 27% from $450M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Avoro Capital Advisors withdrew a net $68.6M in Q3 2016, closing 7 positions and reducing 16 holdings. Its most notable exit was CELATOR PHARMACEUTICALS INC. COMMON STOCK, an estimated $33.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, up from 73% a quarter earlier.

Against the trend, Avoro Capital Advisors opened a new position in GW Pharmaceuticals Plc American Depositary Shares worth $17.7M.

  • Avoro Capital Advisors's largest Q3 2016 buy was GW Pharmaceuticals Plc American Depositary Shares: 133,600 shares worth $17.7M.
  • Avoro Capital Advisors added most to Acadia Pharmaceuticals in Q3 2016, an estimated $15.7M increase.
  • Avoro Capital Advisors's biggest Q3 2016 reduction was TESARO, Inc., cutting an estimated $22.1M.
  • Avoro Capital Advisors fully exited CELATOR PHARMACEUTICALS INC. COMMON STOCK in Q3 2016, selling an estimated $33.9M.
  • Avoro Capital Advisors's ten largest holdings make up 60% of its $570M portfolio in Q3 2016.
  • Avoro Capital Advisors opened 13 new positions and closed 7 in Q3 2016.
  • Avoro Capital Advisors's portfolio value rose 27% quarter-over-quarter to $570M.

Based on Avoro Capital Advisors's 13F filing for Q3 2016, filed 14 Nov 2016.